Entering text into the input field will update the search result below

Biogen's ADUHELM Alzheimer's Pricing: Fiasco Or Second-Level Thinking?

Jan. 06, 2022 7:10 AM ETBiogen Inc. (BIIB)17 Comments
Out of Ignorance profile picture
Out of Ignorance


  • Biogen mishandled its ADUHELM Alzheimer's therapeutic from trial to market.
  • Just in time for Christmas, Biogen took preemptive action nearly halving ADUHELM'S previously announced price.
  • Biogen's ADUHELM trial reversal cast a dark shadow.
  • Biogen's backpedaling on ADUHELM's label and its price were embarrassing strategic blunders or clever second level planning.

Depressed woman sitting on a chair in dark room at home. Lonly , sad, emotion concept.

spukkato/iStock via Getty Images

"Some days you get the bear; some days the bear gets you" or so the old saying goes. Sounds like a basic win or lose proposition. Life is not always so simple. Take for example Biogen's (

This article was written by

Out of Ignorance profile picture
Writing under the pseudonym "out of ignorance", I very much regard investing as a learning process. Investing failures are tuition paid. Investing successes enter the trove of lessons learned. In my Seeking Alpha articles I share my experience from decades of investing and from ~5 years of focused research on a variety of stocks, in recent years with a primary emphasis on healthcare stocks. I greatly appreciate those who take the time to share their reactions to articles, particularly those who share relevant anecdotes and experiences.

Analyst’s Disclosure: I/we have a beneficial long position in the shares of BIIB either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

I may buy or sell interests in any company mentioned over the next 72 hours.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.